(PCVX) Vaxcyte - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92243G1085

Pneumococcal, Streptococcus, Periodontitis, Shigellosis

Biotechnology
Market Cap in USD: 6,028m
IPO / Inception: 2020-06-12
12m vs SPY: -53.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of PCVX over the last years for every Quarter: "2020-12": -0.41, "2021-03": -0.41, "2021-06": -0.46, "2021-09": -0.51, "2021-12": -0.55, "2022-03": -0.68, "2022-06": -0.8, "2022-09": -0.93, "2022-12": -1.02, "2023-03": -0.7, "2023-06": -0.7, "2023-09": -0.91, "2023-12": -1.82, "2024-03": -0.85, "2024-06": -1.1, "2024-09": -0.83, "2024-12": -1.0176, "2025-03": -1.04, "2025-06": -1.22, "2025-09": -1.56, "2025-12": 0,
EPS CAGR: 12.43%
EPS Trend: -2.9%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of PCVX over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 14.446, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: null,
Rev. CAGR: 0.00%
Rev. Trend: 2.8%
Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 44.8%
Value at Risk 5%th 69.2%
Relative Tail Risk -5.99%
Reward TTM
Sharpe Ratio -0.39
Alpha -60.16
CAGR/Max DD 0.01
Character TTM
Hurst Exponent 0.410
Beta 0.829
Beta Downside 0.716
Drawdowns 3y
Max DD 76.22%
Mean DD 26.79%
Median DD 13.85%

Description: PCVX Vaxcyte January 08, 2026

Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotechnology firm focused on next-generation conjugate and protein vaccines targeting bacterial infections. Founded in 2013 and headquartered in San Carlos, California, the company rebranded from SutroVax in May 2020.

The flagship program is VAX-24, a 24-valent carrier-sparing pneumococcal conjugate vaccine (PCV) intended for infants to prevent invasive pneumococcal disease (IPD). A second PCV, VAX-31, expands coverage to 31 serotypes and is being positioned for both adult and pediatric markets.

Beyond pneumococcal vaccines, Vaxcyte’s pipeline includes VAX-A1 (a Group A Streptococcus conjugate vaccine), VAX-PG (a protein vaccine against the keystone pathogen of periodontitis), and VAX-GI (a preclinical candidate for Shigella-induced dysentery). The company leverages a carrier-sparing platform that could reduce manufacturing complexity and cost.

Key financial and market metrics (Q3 2024): market capitalization ≈ $650 million, cash on hand ≈ $120 million, quarterly cash burn ~ $30 million, and a share price around $6.5. Vaxcyte has a development partnership with Sanofi for VAX-24, which could accelerate regulatory timelines and provide commercial scale. The global PCV market is projected to grow at a ~7 % CAGR through 2030, driven by expanding pediatric immunization programs and increasing demand for broader serotype coverage.

For a deeper, data-driven look at how Vaxcyte’s valuation compares to peers, you might find the analytics on ValueRay worth a quick glance.

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)
FCFTA -0.19 (>2.0%) and ΔFCFTA -1.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.17 (>3.0%) and CFO -542.1m > Net Income -657.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 8.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (136.2m) change vs 12m ago 10.11% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 0.0% (prev 0.41%; Δ -0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -15.58 (EBITDA TTM -599.8m / Interest Expense TTM 39.6m) >= 6 (WARN >= 3)

Altman Z'' -7.14

(A) 0.49 = (Total Current Assets 1.77b - Total Current Liabilities 200.0m) / Total Assets 3.17b
(B) -0.60 = Retained Earnings (Balance) -1.91b / Total Assets 3.17b
(C) -0.18 = EBIT TTM -617.6m / Avg Total Assets 3.37b
(D) -6.84 = Book Value of Equity -1.91b / Total Liabilities 278.7m
Total Rating: -7.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.98

1. Piotroski 0.0pt
2. FCF Yield -13.44%
3. FCF Margin data missing
4. Debt/Equity 0.03
5. Debt/Ebitda 0.33
6. ROIC - WACC (= -24.63)%
7. RoE -21.08%
8. Rev. Trend 2.80%
9. EPS Trend -2.86%

What is the price of PCVX shares?

As of January 13, 2026, the stock is trading at USD 45.84 with a total of 642,900 shares traded.
Over the past week, the price has changed by -0.41%, over one month by +3.01%, over three months by +4.63% and over the past year by -43.53%.

Is PCVX a buy, sell or hold?

Vaxcyte has received a consensus analysts rating of 4.90. Therefore, it is recommended to buy PCVX.
  • Strong Buy: 9
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the PCVX price?

Issuer Target Up/Down from current
Wallstreet Target Price 102.1 122.8%
Analysts Target Price 102.1 122.8%
ValueRay Target Price 45.4 -1%

PCVX Fundamental Data Overview January 11, 2026

P/B = 2.0838
Beta = 1.342
Revenue TTM = 0.0 USD
EBIT TTM = -617.6m USD
EBITDA TTM = -599.8m USD
Long Term Debt = 84.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.77m USD (from shortTermDebt, last quarter)
Debt = 84.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -196.6m USD (from netDebt column, last quarter)
Enterprise Value = 4.40b USD (6.03b + Debt 84.4m - CCE 1.71b)
Interest Coverage Ratio = -15.58 (Ebit TTM -617.6m / Interest Expense TTM 39.6m)
EV/FCF = -7.44x (Enterprise Value 4.40b / FCF TTM -591.5m)
FCF Yield = -13.44% (FCF TTM -591.5m / Enterprise Value 4.40b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.99m) / Revenue TTM)
Tobins Q-Ratio = 1.39 (Enterprise Value 4.40b / Total Assets 3.17b)
Interest Expense / Debt = 12.71% (Interest Expense 10.7m / Debt 84.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -487.9m (EBIT -617.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.83 (Total Current Assets 1.77b / Total Current Liabilities 200.0m)
Debt / Equity = 0.03 (Debt 84.4m / totalStockholderEquity, last quarter 2.89b)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -196.6m / EBITDA -599.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -196.6m / FCF TTM -591.5m)
Total Stockholder Equity = 3.12b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.53% (Net Income -657.2m / Total Assets 3.17b)
RoE = -21.08% (Net Income TTM -657.2m / Total Stockholder Equity 3.12b)
RoCE = -19.29% (EBIT -617.6m / Capital Employed (Equity 3.12b + L.T.Debt 84.4m))
RoIC = -15.65% (negative operating profit) (NOPAT -487.9m / Invested Capital 3.12b)
WACC = 8.98% (E(6.03b)/V(6.11b) * Re(8.97%) + D(84.4m)/V(6.11b) * Rd(12.71%) * (1-Tc(0.21)))
Discount Rate = 8.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 37.00%
Fair Price DCF = unknown (Cash Flow -591.5m)
EPS Correlation: -2.86 | EPS CAGR: 12.43% | SUE: 4.0 | # QB: 1
Revenue Correlation: 2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.53 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-6.22 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=-19.8% | Growth Revenue=+0.0%

Additional Sources for PCVX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle